Literature DB >> 16205778

Cocaine self-administration reduces excitatory responses in the mouse nucleus accumbens shell.

Nicole L Schramm-Sapyta1, Christopher M Olsen, Danny G Winder.   

Abstract

Drugs of abuse affect behavior by altering neuronal communication within the brain. Previous research examining the effects of intraperitoneally administered cocaine has revealed that cocaine alters excitatory glutamatergic signaling, both directly through regulation of synaptic function, and indirectly through regulation of cellular excitability in areas of the drug reward circuitry such as the nucleus accumbens (NAcc) and ventral tegmental area. We have now extended these findings by testing the hypothesis that self-administration of cocaine might elicit similar alterations in excitatory signaling in the NAcc shell. We observed that cocaine self-administration reduces synaptically evoked excitatory responses recorded extracellularly in the NAcc shell compared to saline self-administration. This alteration was not accompanied by alterations in paired pulse ratio of synaptically evoked responses or in potentiation of these responses by application of the adenylyl cyclase activator forskolin. This reduction in glutamatergic signaling may be one mechanism by which cocaine exerts its long-term behavioral effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16205778     DOI: 10.1038/sj.npp.1300918

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  32 in total

1.  Temporally dependent changes in cocaine-induced synaptic plasticity in the nucleus accumbens shell are reversed by D1-like dopamine receptor stimulation.

Authors:  Pavel I Ortinski; Fair M Vassoler; Gregory C Carlson; R Christopher Pierce
Journal:  Neuropsychopharmacology       Date:  2012-03-14       Impact factor: 7.853

Review 2.  Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction.

Authors:  M Foster Olive
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

3.  Continuous exposure to the competitive N-methyl-D: -aspartate receptor antagonist, LY235959, facilitates escalation of cocaine consumption in Sprague-Dawley rats.

Authors:  Richard M Allen; Linda A Dykstra; Regina M Carelli
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

4.  Acute amphetamine exposure selectively desensitizes kappa-opioid receptors in the nucleus accumbens.

Authors:  Yan-fang Xia; Li He; Jennifer L Whistler; Gregory O Hjelmstad
Journal:  Neuropsychopharmacology       Date:  2007-06-06       Impact factor: 7.853

5.  Group I mGluRs and long-term depression: potential roles in addiction?

Authors:  Brad A Grueter; Zoé A McElligott; Danny G Winder
Journal:  Mol Neurobiol       Date:  2007-07-27       Impact factor: 5.590

Review 6.  AMPA receptor plasticity in the nucleus accumbens after repeated exposure to cocaine.

Authors:  Marina E Wolf; Carrie R Ferrario
Journal:  Neurosci Biobehav Rev       Date:  2010-01-28       Impact factor: 8.989

Review 7.  Synaptic plasticity in the mesolimbic system: therapeutic implications for substance abuse.

Authors:  Billy T Chen; F Woodward Hopf; Antonello Bonci
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

8.  Operant sensation seeking engages similar neural substrates to operant drug seeking in C57 mice.

Authors:  Christopher M Olsen; Danny G Winder
Journal:  Neuropsychopharmacology       Date:  2009-01-14       Impact factor: 7.853

9.  Nicotine addiction reduces the large-conductance Ca(2+)-activated potassium channels expression in the nucleus accumbens.

Authors:  Lan Ma; Yu-Mei Wu; Yan-Yan Guo; Qi Yang; Bin Feng; Qian Song; Shui-Bing Liu; Da-Qing Zhao; Ming-Gao Zhao
Journal:  Neuromolecular Med       Date:  2012-12-16       Impact factor: 3.843

Review 10.  Neuroplasticity in the mesolimbic dopamine system and cocaine addiction.

Authors:  M J Thomas; P W Kalivas; Y Shaham
Journal:  Br J Pharmacol       Date:  2008-03-17       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.